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Abstract
Sensitization to the effects of drugs of abuse and associated stimuli contributes to drug craving, compulsive drug use, and
relapse in addiction. Repeated opiate exposure produces behavioral sensitization that is hypothesized to result from neural
plasticity in specific limbic, striatal and cortical systems. DFosB and FosB are members of the Fos family of transcription
factors that are implicated in neural plasticity in addiction. This study examined the effects of intermittent morphine
treatment, associated with motor sensitization, on FosB/DFosB levels using quantitative immunohistochemistry. Motor
sensitization was tested in C57BL/6 mice that received six intermittent pre-treatments (on days 1, 3, 5, 8, 10, 12) with either
subcutaneous morphine (10 mg/kg) or saline followed by a challenge injection of morphine or saline on day 16. Mice
receiving repeated morphine injections demonstrated significant increases in locomotor activity on days 8, 10, and 12 of
treatment (vs. day 1), consistent with development of locomotor sensitization. A morphine challenge on day 16 significantly
increased locomotor activity of saline pre-treated mice and produced even larger increases in motor activity in the
morphine pre-treated mice, consistent with the expression of opiate sensitization. Intermittent morphine pre-treatment on
these six pre-treatment days produced a significant induction of FosB/DFosB, measured on day 16, in multiple brain regions
including prelimbic (PL) and infralimbic (IL) cortex, nucleus accumbens (NAc) core, dorsomedial caudate-putamen (CPU),
basolateral amygdala (BLA) and central nucleus of the amygdala (CNA) but not in a motor cortex control region. Opiate
induced sensitization may develop via Fos/DFosB plasticity in motivational pathways (NAc), motor outputs (CPU), and
associative learning (PL, IL, BLA) and stress pathways (CNA).
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Introduction
Sensitization is an addiction-related phenomenon that pro-
duces enduring enhancement of behavioral or locomotor
responses after repeated and intermittent administration of
psychostimulants and opiates [1]. Extensive investigations have
shown that the repeated administration of psychostimulants such
as cocaine, amphetamine, and nicotine result in persistent motor
and neurochemical sensitization in animal models [2,3].
Sensitization to drugs of abuse and associated stimuli is
hypothesized to occur via plasticity in motor, motivational and
cognitive neural systems and is thought to contribute to drug
craving and relapse in addiction. Sensitization develops to the
stimulant effects of opiates [4,5] and to their conditioned
rewarding properties, as measured by conditioned place
preference [6,7]. Sensitization develops to the conditioned
aversive effects of withdrawal after repeated drug administration
[8]. Thus, addiction can be viewed as a progressive phenomenon
resulting partly from the sensitization of the stimulant and
rewarding effects of drugs and from the conditioned aversive
properties of drug withdrawal. Sensitization can last for days,
weeks or months after cessation of drug exposure and is thought
to contribute to relapse in addiction [9].
Mesocorticolimbic and nigrostriatal dopaminergic pathways are
two major ascending circuits that regulate behavior, motor
activity, reward, and reinforcement in the brain [10,11,12].
Mesocorticolimbic pathways originating from the ventral tegmen-
tal area innervate the medial prefrontal cortex, the ventral
striatum (nucleus accumbens or NAc) and the amygdala while
the nigrostriatal dopaminergic pathway originates from the
substantia nigra and projects to the dorsal striatum (caudate
putamen or CPU). The nigrostriatal dopaminergic pathway plays
a key role in movement initiation, learning of motor patterns
[3,12] and drug-related habit learning [10,11,12]. The mesocorti-
colimbic dopaminergic circuit plays a key role in the locomotor
stimulant, rewarding, and sensitizing properties of drugs of abuse
[12,13]. Dopaminergic projections to medial prefrontal cortex and
amygdala are critical in the development of psychostimulant
sensitization [3,14,15]. However, the mechanisms and neural
pathways involved in opiate sensitization are not well understood.
Sensitization has been shown to produce plasticity in striatal
pathways as measured by induction of transcription and
translation of new proteins. Transcription factor DFosB, a
truncated splice isoform of FosB from the immediate early-gene
Fos family, has been considered to be critical in the regulation of
brain dopaminergic systems following repeated drug administra-
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persistent in specific brain regions for long periods of time after
their induction [16,17,18]. DFosB induction and expression are
thought to be responsible for specific neuroplastic changes after
chronic administration of drugs of abuse that include cocaine
[19,20], nicotine [21], ethanol [20], and D
9-THC, the active
compound in marijuana [20]. FosB and DFosB accumulate in a
region-specific manner in the brain and are induced in the NAc
and dorsal striatum (CPU) following drug administration.
Overexpression of DFosB enhances sensitivity to the rewarding
and locomotor-activating effects of cocaine [20,22,23,24,25,26].
Additionally, DFosB mutant mice (vs. wild-type controls) showed
increased motor responses to a single cocaine dose and enhanced
conditioned place preference to a lower dose of cocaine [27].
Mutant mice, however, did not demonstrate further increases in
activity after cocaine sensitization.
Studies have not yet examined relationships between neural
FosB/DFosB expression and opiate sensitization in cortical or
limbic brain regions. Different chronic opiate administration
paradigms activate FosB/DFosB in accumbal [20,28,29] and
cortical [20] regions but the associated behavioral effects of
morphine treatment were not linked to such changes. In our syudy
of overexpression of DFosB did increase the rewarding and
withdrawal properties of repeated morphine treatment [26]. In
another important study [30], the association between opiate
sensitized motor behaviors and DFosB levels have been demon-
strated in striatum and ventral pallidum brain regions. There are
other diverse functional neural pathways that contribute to opiate
sensitization including cognitive, motivational, motor and associa-
tive circuitry. It is critical to examine linkages between opiate
sensitized behaviors and FosB/DFosB levels in a variety of relevant
brain regions. We examined the ability of repeated and
intermittent morphine administration to induce locomotor sensi-
tization in C57BL/6 mice and then assayed FosB/DFosB
immunoreactivity in cortical, striatal and amygdala regions using
quantitative immunohistochemistry.
Materials and Methods
Animals and housing conditions
Male C57BL/6 mice weighing 24–26 g (Charles River
Laboratories, NC) were used in all experiments and were chosen
because of their demonstrated sensitivity to the behavioral effects
of morphine stimulation. The animal facility was approved by the
Association for the Assessment and Accreditation of Laboratory
Animal Care (AAALAC). Mice were housed under standard
vivarium conditions in a temperature and humidity controlled
environment where they were allowed food and water ad libitum.
Animals were kept under a 12:12 h light-dark illumination cycle
and acclimated to the colony environment for 7 days prior to all
experiments. Drug treatments and behavioral monitoring began
after 0700 h and ended before 1700 h. Animal use procedures
were approved by the Veterans Affairs Medical Center Animal
Care and Use Committee and were conducted in accordance with
the NIH Guide for the Care and Use of Laboratory Animals.
Locomotor activity and morphine sensitization treatment
regimen
Open field activity test. Locomotor activity was measured
with an automated infrared activity monitoring system from Med
Associates (43.2 cm643.2 cm; St. Albans, VT) containing 16
infrared beams in the horizontal plane. Activity boxes were placed
in sound attenuation chambers to avoid most environmental
sounds in the test room. The locomotor activity associated with
horizontal locomotion was defined as the total distance traveled
(cm).
Treatment regimen. A morphine dose of 10 mg/kg (s.c.)
has been well-established to induce sensitization in previous studies
[2,4,5,6,31]. This dose was also chosen because of findings that
chronic morphine at a dose 10 mg/kg increased DFosB levels in
the nucleus accumbens and ventral pallidum [30]. For both
behavioral and neurochemical studies, mice were assigned to the
repeated vehicle treatment or repeated morphine treatment
groups (n=8–16 per group). For behavioral comparisons, other
mice were assigned to the vehicle pre-treatment group and
received morphine challenge on day 16 or to morphine pre-
treatment and received vehicle challenge on day 16. To determine
the effect of intermittent morphine administration on the
development or expression of behavioral sensitization, mice were
pre-treated with either morphine (10 mg/kg, s.c.) or sterile saline
(10 ml/kg, s.c.) injections once a day on days 1, 3, 5, 8, 10, and 12
(total of 6 administrations). All mice were allowed to acclimate to
the activity testing boxes for 30 min prior to any treatment to
minimize novelty effects. Locomotor activity, measured as the total
distance traveled in centimeters, was monitored and recorded
immediately after each injection at 15 min intervals for 180 min.
To examine the expression of intermittent morphine-induced
sensitization, mice received a single challenge injection of either
morphine or saline on day 16 after a 3-day treatment-free period
and the locomotor activity was subsequently examined as above.
The anesthetic sodium pentobarbital (80 mg/kg, i.p.) was used to
euthanize mice at the end of all experiments.
FosB/DFosB immunohistochemistry
The effect of repeated morphine versus vehicle pre-treatments
on FosB/DFosB induction in the brain was examined after vehicle
injection and locomotor monitoring on day 16. Mice were
anaesthetized and underwent intracardiac perfusion with ice-cold
phosphate buffered saline (PBS) followed by 4% paraformalde-
hyde in 0.2 M phosphate buffer. Brains were removed quickly and
post-fixed in a series: 4% paraformaldehyde, 12.5% sucrose in
PBS, and 25% sucrose in PBS (24 h each). FosB/DFosB
immunoreactivity was examined in free floating sections as
described in a previous publication [31]. Brain regions studied
were based on findings from other drug sensitization studies.
Briefly, coronal sections (40 mm) from prelimbic cortex (PL),
infralimbic cortex (IL), the NAc core (NAcC) and shell (NAcS),
dorsal medial caudate-putamen (CPU), the central nucleus of
amygdala (CNA) and the basolateral amygdala (BLA) regions were
cut on a freezing cryostat. After blocking with 1.5% normal goat
serum for 1 h, sections were incubated overnight at 4uC with the
primary antibody, a rabbit polyclonal FosB antiserum (sc-48;
Santa Cruz Biotechnology, CA, dilution 1:750 in PBS containing
1.5% goat serum) that recognizes both FosB and isoforms of
DFosB. Sections were then washed and incubated for 1 h at room
temperature in secondary antibody, biotinylated goat anti-rabbit
IgG (Santa Cruz Biotechnology, Santa Cruz, CA, dilution 1:2000
in PBS). FosB/DFosB immunoreactivity was visualized by the
biotin-streptavidin technique (ABC Staining System; Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) using 3, 39diaminobenzidine
(ImmunoPure Metal Enhanced DAB; Pierce, Rockford, IL) as the
chromagen.
Quantitation of FosB/DFosB immunoreactivity
Changes in FosB/DFosB immunoreactivity were measured in
sections from prefrontal cortices (PL, IL), striatal (NAcC and
NAcS, CPU), and amygdala (CNA and BLA) brain regions.
Quantitative measurement was performed using a computer-
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bright field microscope interfaced with a color digital camera
(MicroFire; Optronics, Goletta, CA ), and a computer with Image-
Pro Plus image processing & analysis software (Version 6.3; Media
Cybernetics, Silver Spring, USA). Images were obtained at 106
magnification and were averaged from right and left hemispheres
in each subject. FosB/DFosB-positive nuclei were considered to be
signals showing grayscale contrast levels over 125 units (total
possible range was 0–255) in order to eliminate very lightly stained
nuclei constitutively present in the brain. The individuals
performing the analyses were blinded to treatment conditions.
Statistical analysis
For pre-treatment studies (days 1–12), two-way ANOVA was
used to analyze the influence of morphine vs. saline pre-treatments
(as the between-group factors) and the day of treatment (as the
within-group factor) as well as the treatment by time interaction on
locomotor activity. For locomotor activity on day 16 of treatment,
one-way ANOVA was used to analyze the influence of treatment
groups. Bonferroni tests were used to determine differences
between individual treatment groups for locomotor activity. T-
test comparisons were used to examine treatment effects (vehicle
pre-treatment vs morphine pre-treatment) on FosB/DFosB levels
in each brain region. P,0.05 was considered statistically
significant. Outlier analyses were performed for treatment groups
and a data outlier was defined if its standard score is 62.5
standard deviations from the mean [32]. There were only three
data point outliers identified; these were not included in analyses.
Results
Figure 1 illustrates the motor effects of intermittent morphine
administration given on days 1, 3, 5, 8, 10, and 12 of pre-
treatment, as measured by the total distance traveled over
180 min. A two-way ANOVA demonstrated significant effects of
treatment (vehicle vs. morphine) group (F1, 232=235.4;
P,0.0001), treatment day (F5, 232=3.47; P,0.01) and treatment
group6day interaction (F5, 232=3.39; P,0.0001). Post-hoc testing
revealed that on days 8, 10, and 12 of treatment, the morphine
treatment groups showed significant differences in locomotor
responses compared with day 1 of treatment. Thus, repeated
morphine pre-treatment produced increasing motor stimulant
effects within four to six treatments resulting in the development of
locomotor sensitization in this model.
Figure 2A shows the locomotor activity values for three different
treatment groups: vehicle pre-treatment/vehicle challenge, vehicle
pre-treatment/morphine challenge, and morphine pre-treatment/
morphine challenge. On the challenge day, the vehicle pre-
treatment group receiving morphine challenge showed a 5-fold
increase in mean distance traveled (vs. vehicle/vehicle controls).
The morphine pre-treatment group receiving morphine challenge
showed a 12-fold increase in motor activity (vs. vehicle pre-
treatment/morphine challenge). These results show a model for
the expression of morphine sensitization. One-way ANOVA
shows significant differences in activity levels for these three
treatment groups (F2, 23=101.9; P,0.0001). Figure 2B illustrates
the time course (at 15 min intervals) of locomotor response to a
morphine challenge injection over 180 min on day 16. On
challenge day, mice receiving morphine showed maximum activity
levels reached at 60 to 90 min and demonstrate increased
stimulant effects of morphine challenge after morphine pre-
treatment. These results suggest that after six pre-treatments,
morphine administration on day 16 induces the expression of
morphine sensitization.
Figure 3 shows schematic diagrams of coronal sections of mouse
brains and illustrates locations of FosB/DFosB immunoreactivity
quantitation in PL, IL, NAcC, NAcS, CPU, and BLA regions and
a control motor region (M1/2). The black squares correspond to a
fixed area 200 mm6200 mm. In the PL, the square was placed
equal in the center of PL (1.70 to 1.42 mm). In the IL, the square
was placed equal in the center of IL (1.70 to 1.42 mm). In the M1/
2, the square was placed the centrally at the border between M1
and M2 (1.70 to 1.42 mm). In the NAcC, the left vertical length of
the square was placed medial to the anterior commissure and the
top horizontal width was placed above the anterior commissure
(1.54 to 0.98 mm). In the NAcS, the right vertical length of the
square was placed lateral to the major islands of Calleja and the
top horizontal width was placed with the dorsal edge at equal
height with the anterior commissure (1.54 to 0.98 mm). In the
CPU, the rectangle was placed at the top of the lateral ventricle
Figure 1. Intermittent morphine administration results in the development of locomotor sensitization in C57BL/6 mice. Mice were
given either a saline (10 mg/ml) or morphine (10 mg/kg) injection on days 1, 3, 5, 8, 10, 12 and a locomotor activity test was conducted and recorded
immediately after each injection for 180 min. Data are recorded as total distance traveled for 180 min and shown as total distance traveled (cm) 6
S.E.M in each treatment group (n=8–16 mice per group). *P,0.05 in comparison to the morphine treated group’s first day of testing.
doi:10.1371/journal.pone.0023574.g001
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were placed inside the CNA (21.06 to 21.34 mm) and inside the
BLA (21.06 to 21.34 mm).
FosB and DFosB are neural transcription factors which
measure adaptive changes following morphine treatment and
were assayed by quantitative immunohistochemistry. Figure 4
shows representative photomicrographs of FosB/DFosB-positive
nuclei in brain regions which include PL, IL, M1/2, NAcC,
NAcS, CPU, CNA and BLA. FosB/DFosB-positive nuclei were
quantified inside a field of 200 mm6200 mmw i t h i ne a c hb r a i n
region of interest. Figure 5 illustrates mean counts of FosB/
DFosB-positive nuclei in brains from the morphine pre-treatment
group and vehicle pre-treatment groups that were harvested from
mice following vehicle injection and motor activity testing on day
16. For each treatment group, mean counts from bilateral regions
were averaged and analyzed via ANOVA procedures. T-test
comparisons demonstrated significant effects of repeated mor-
phine treatment on FosB/DFosB levels in each of the following
brain regions: PL (t=3.1; P,0.01), IL (t=3.7; P,0.005), NAcC
(t=3.2; P,0.005), CPU (t=4.0; P,0.001), BLA (t=3.9;
P,0.001) and CNA (t=2.8; P,0.05) and no differences in
M1/2.
Figure 2. Intermittent morphine administration results in the expression of locomotor sensitization in C57BL/6 mice. A) Mice were
given either a saline or morphine (10 mg/kg, s.c.) injection on days 1, 3, 5, 8, 10, and 12. On the challenge day (day 16), mice were treatment-free for a
three day period and then received a single challenge dose of morphine (10 mg/kg) or saline. Locomotor activity tests were performed for 180 min
immediately after drug injections and data are recorded as total distance traveled (cm) 6 S.E.M in each treatment group (n=8 mice per group).
*P,0.05 vs. vehicle pre-treatment/vehicle challenge group; # P,0.05 vs. vehicle pre-treatment/morphine challenge group. B) The time course of
opiate sensitization (measured in 15 min intervals) is demonstrated on challenge day after three treatment-free days from intermittent morphine
administration on day 16.
doi:10.1371/journal.pone.0023574.g002
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In summary, repeated and intermittent morphine injections
produced progressive increases in motor activity. In morphine pre-
treated mice, a morphine injection on challenge day (day 16)
produced more than a two-fold increase in locomotor behavior
compared to vehicle pre-treated mice (receiving the same
morphine challenge). Morphine sensitized mice demonstrated
associated increases in FosB/DFosB immunoreactivity in PL, IL,
NAcC, NAcS, CPU, CNA, and BLA regions.
Opiate sensitization has been characterized by an increased
sensitivity enhancement to the effects of opiates after prolonged
exposure [1]. Its development and expression depend on dose and
duration of drug administration as well as the withdrawal time
from the last exposure to the drug [33,30]. The intermittent
morphine treatment regimen in our study produced progressively
larger increases in the locomotor response to morphine consistent
with previous results and the dose administered is comparable to
previously demonstrated ranges [4,5,30,31,33,34,35].
Transcription factor DFosB is a highly stable protein induced in
the brain’s reward regions by chronic exposure to many drugs of
abuse and is an important regulator of both dopaminergic and
glutamatergic transmission in the brain [17,26,28,30,36,37]. It is
well documented that this transcription factor accumulates in the
brain as a result of exposure to a variety of stimuli, including drugs
of abuse [16,38,39]. Previous studies have shown that DFosB
accumulates with repeated exposure to drugs of abuse and remains
at high levels in the brain for weeks [18,40,41] representing a
potential mechanism underlying the long-lasting neuroadaptation.
It has been shown that DFosB is induced after repeated exposures
to drugs of abuse [17,20,38] and in cocaine sensitization [19].
Over-expression of DFosB in nucleus accumbens and dorsal
striatum increased locomotor and rewarding responses to both
cocaine and morphine [9,22,26]. One previous study had
demonstrated FosB/DFosB induction in accumbal and ventral
pallidal regions in opiate sensitization [30] but it did not examine
such effects in cortical, dorsal striatal, and limbic brain regions as
demonstrated in this report.
This study demonstrates the importance of FosB transcription
factors and neuroadaptive responses in cortical and amygdala
brain regions in opiate sensitization. It highlights that diverse
pathways contribute to opiate sensitization including cognitive,
motivational, motor and associative neural circuits. Mueller and
Unterwald [28] demonstrated that repeated and increasing doses
of morphine, but not acute morphine, produced increases in
DFosB-immunoreactivity in the NAc, CPU and PL. Zachariou
and colleagues [26] demonstrated that DFosB over-expression in
the NAc enhanced sensitivity to morphine reward and depen-
dence. McDaid and coworkers [30] demonstrated that morphine-
induced behavioral sensitization was associated with elevated
accumbal and pallidal DFosB levels following a 3-day withdrawal
that returned to baseline in 14 days. Our results are consistent with
these findings and all studies highlight the importance of accumbal
FosB/DFosB induction as a plasticity marker in opiate addiction.
This study presents new findings in which opiate sensitization
produces neuroadaptive effects in executive (PL, IL), motivational
(NAc), motor (CPU), and associative learning (BLA) pathways.
The PFC is responsible for executive function, decision-making,
and the implementation of goal-directed actions. Subregions of the
PFC include the PL, which guides response initiation and the IL
which mediates response inhibition; both regions guide actions
and outcomes. The PL and IL may serve as on-off mechanisms in
both conditioned drug and fear responses [42,43]. The BLA
processes emotion-related drug stimuli and mediates approach or
avoidance behavior. The NAc connects input from limbic sites
related to drug reward to behavioral output through the ventral
pallidum. The CNA is a major output area for stress responses.
A role for mesocorticolimbic dopamine neurons has been
previously demonstrated in opiate sensitization. Repeated and
intermittent morphine treatment produced an enhancement of
motor activity associated with increases in mesolimbic dopamine
transmission [2,44,45]. Because the NAc receives glutamatergic
Figure 3. Schematic diagrams of coronal sections of mice brain
illustrating where FosB/DFosB immunoreactivity was quanti-
fied in the following regions: prelimbic cortex (PL), infralimbic
cortex (IL), motor cortex (M1/2), nucleus accumbens core
(NAcC), nucleus accumbens shell (NAcS), caudate-putamen
(CPU), central nucleus of amygdala (CNA) and basolateral
amygdala (BLA). The black squares correspond to a fixed area
200 mm6200 mm in size.
doi:10.1371/journal.pone.0023574.g003
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functions as an interface for dopamine-glutamate interactions. The
NAc regulates both emotional and behavioral responses and is
implicated in the expression of behavioral sensitization to opiates
[3,14]. It is likely that the enhanced locomotor sensitivity induced
by intermittent morphine treatment in the present study is
accompanied by long-lasting synaptic adaptations in these
dopaminergic and glutamatergic neurons [3,46] that appears to
be produced by DFosB mechanisms.
However, comparisons between different sensitization studies is
challenging because dopaminergic systems are responsive to
various parameters of morphine treatment including morphine
dose, time between withdrawal and challenge treatment, as well as
genetic background of animals and species differences [45,47,48].
A limitation of this study is that the antibody used measures both
FosB and DFosB proteins, so future studies can examine these
transcription factors separately in these various regions. Since
diverse pathways are activated during opiate sensitization, future
studies might also examine how plasticity in motivational and
associative circuits along with motor outputs may contribute
individually and interactively to opiate sensitization responses.
Future translational research is needed to examine behavioral and
neurobiological mechanisms of enduring hyper-responsivity to
drug sensitization associated structural plasticity which underlies
Figure 4. DFosB/FosB expression was determined by immunohistochemistry using anti-FosB/DFosB polyclonal antibody in multiple
sections. These representative photomicrographs (10-fold magnification) demonstrate FosB/DFosB immunoreactive nuclei in PL, IL, M1/2, NAcC,
NAcS, CPU, CNA and BLA brain regions. They were collected from vehicle and morphine pre-treatment treatment groups following vehicle injection
and motor activity testing on day 16. The landmarks include: ACa, anterior commissure, and LV, lateral ventricle.
doi:10.1371/journal.pone.0023574.g004
Figure 5. Quantitative analyses of FosB/DFosB immunoreactivity from subjects from the vehicle and morphine pre-treatment
groups following vehicle injection and motor activity testing on day 16. The quantification of the DFosB/FosB expression was determined
by immunohistochemistry from multiple sections in each of the following brain regions: PL, IL, M1/2, NAcC, NAcS, CPU, CNA and BLA. Data are shown
as mean 6 S.E.M of n=4–8 mice from each treatment group. *P,0.05, **P,0.01, and ***P,0.001 vs. vehicle pre-treatment group.
doi:10.1371/journal.pone.0023574.g005
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opiate sensitization produces the induction of FosB/DFos plasticity
in executive (PL, IL), motivational (NAc), motor (CPU), and
associative learning (BLA) pathways.
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